Overview

BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
2017-03-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out the good and bad effects that occur when BKM120 is added to standard chemotherapy with carboplatin and paclitaxel.
Phase:
Phase 1
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Novartis Pharmaceuticals
Sai Life Sciences
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel